Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

A new biotech company has grown out of laboratory and clinical studies at the Medical College of Georgia with the goal of improving the diagnosis and treatment of diabetes and cancer.

20 Jul 2010

Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

From Novo Nordisk 20 Jul 2010

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

From Novo Nordisk 19 Jul 2010

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Take a skin cell from a patient with Type 1 diabetes. Strip out everything that made it a skin cell, then reprogram it to grow into a colony of pancreatic beta cells. Implant these into your patient and voilà! She's producing her own insulin like a pro.

19 Jul 2010

AMPK may regulate epigenetic mechanism: Research

AMP-activated protein kinase, or AMPK, is a master regulator protein of metabolism that is conserved from yeast to humans. When a cell is low on fuel, AMPK shuts down processes that use energy and turns on processes that produce energy.Biologists have been studying how AMPK works for several decades and know that once it is activated, AMPK turns on a large number of genes by passing the "make more energy" message through numerous signaling cascades in the cell. What was not known, until now, was that AMPK also works via an epigenetic mechanism to slow down or stop cell growth.

17 Jul 2010

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

The Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists issue joint statement in response to an FDA panel's recommendation to keep rosiglitazone (Avandia) on the market

16 Jul 2010

Two-thirds of world's population are vitamin D-insufficient or deficient

Vitamin D surfaces as a news topic every few months. How much daily vitamin D should a person get? Is it possible to have too much of it? Is exposure to the sun, which is the body's natural way of producing vitamin D, the best option? Or do supplements suffice?

16 Jul 2010

VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.

16 Jul 2010

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Diamyd Medical AB has received antitrust clearance that closes the transaction announced on June 22, 2010 with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company.

16 Jul 2010

VCU Medical Center ranked in 2010-2011 Best Hospitals

The Virginia Commonwealth University Medical Center on Thursday was ranked in the 2010-2011 Best Hospitals in the country by U.S. News and World Report, making it one of 152 medical centers nationwide selected out of nearly 2,000 eligible institutions.

16 Jul 2010

Proteinuria screening identifies risk for kidney disease progression

A morning urine test is superior to all other tests for detecting declining kidney performance in patients with diabetic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that clinicians should monitor kidney function by measuring the albumin:creatinine ratio from a first morning urine sample.

16 Jul 2010

MPI reduces depressive symptoms: Study

This randomized controlled trial aimed to evaluate the effectiveness of a nurse-led minimal psychological intervention (MPI) in chronically ill elderly persons with minor depression or mild-to-moderate major depression, and type II diabetes or chronic obstructive pulmonary disease. Nine months after the intervention, patients receiving the MPI showed a 50% reduction in depressive symptoms relative to baseline values and diabetic MPI patients had a better quality of life than diabetic controls.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Type 1 diabetes affects athletic performance, new study finds

A new study led by York University researchers finds that young athletes with Type 1 diabetes may experience a marked decrease in performance as a result of their blood sugar levels.

15 Jul 2010

New circular external fixator device for diabetic Charcot foot treatment

The alarming increase of morbidly obese diabetics is causing more new cases of a debilitating foot deformity called Charcot foot.Charcot foot can make walking difficult or impossible, and in severe cases can require amputation.But a surgical technique that secures foot bones with an external frame has enabled more than 90 percent of patients to walk normally again.

15 Jul 2010

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

After two days of hearings, an advisory committee to the U.S. Food and Drug Administration (FDA) recommended that the FDA allow the type 2 diabetes drug rosiglitazone (brand name, Avandia), to stay on the market, but with most committee members suggesting that the label be revised to include increased warnings. Rosiglitazone is one in a class of drugs called thiazolidinediones (TZDs), used to treat type 2 diabetes.

15 Jul 2010

Children's National and George Washington University receive NIH Clinical and Translational Science Award

Children's National Medical Center, in partnership with The George Washington University Medical Center, has received a prestigious Clinical and Translational Science Award (CTSA) from the National Center for Research Resources of the National Institutes of Health.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

AMPK may regulate epigenetic mechanism: Research

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

Two-thirds of world's population are vitamin D-insufficient or deficient

VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

VCU Medical Center ranked in 2010-2011 Best Hospitals

Proteinuria screening identifies risk for kidney disease progression

MPI reduces depressive symptoms: Study

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Type 1 diabetes affects athletic performance, new study finds

New circular external fixator device for diabetic Charcot foot treatment

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

Children's National and George Washington University receive NIH Clinical and Translational Science Award

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in